Alexander, Robert

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery

Pharmaceutical Economics and PolicyComputational Drug Discovery Methods

Cited by 1,344

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer’s disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.

Burns, D. K., Alexander, R. C., Welsh-Bohmer, K. A., Culp, M., Chiang, C., O’Neil, J., Evans, R. M., Harrigan, P., Plassman, B. L., Burke, J. R., et al. (2021) · The Lancet Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 130

Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study

Adams, J. L., Kangarloo, T., Tracey, B., O’Donnell, P., Volfson, D., Latzman, R. D., Zach, N., Alexander, R., Bergethon, P., Cosman, J., et al. (2023) · npj Parkinson's Disease

Parkinson's Disease Mechanisms and TreatmentsContext-Aware Activity Recognition Systems

Cited by 98

Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies

Ratti, E., Bettica, P., Alexander, R., Archer, G., Carpenter, D., Evoniuk, G., Gomeni, R., Lawson, E., Lopez, M., Millns, H., et al. (2013) · Journal of Psychopharmacology

Treatment of Major DepressionNeuropeptides and Animal Physiology

Cited by 69

Combined NK 1 antagonism and serotonin reuptake inhibition: effects on emotional processing in humans

Harmer, C. J., Dawson, G. R., Dourish, C. T., Favaron, E., Parsons, E., Fiore, M., Zucchetto, M., Bifone, A., Poggesi, I., Fernandes, S., et al. (2013) · Journal of Psychopharmacology

Treatment of Major DepressionNeurotransmitter Receptor Influence on Behavior

Cited by 24